| 1 |
Parham KA, Kim GN, Richer CG, Ninkov M, Wu K, Saeedian N, Li Y, Rashu R, Barr SD, Arts EJ, Haeryfar SMM, Kang CY, Troyer RM. Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8(+) T cells against SARS-CoV-2 variants. iScience 2023;26:106292. [PMID: 36915805 DOI: 10.1016/j.isci.2023.106292] [Reference Citation Analysis]
|
| 2 |
Tisoncik-go J, Voss KM, Lewis TB, Muruato AE, Kuller L, Finn EE, Betancourt D, Wangari S, Ahrens J, Iwayama N, Grant RF, Murnane RD, Edlefsen PT, Fuller DH, Barber GN, Gale M, O’connor MA. Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina. Front Virol 2023;3. [DOI: 10.3389/fviro.2023.1108420] [Reference Citation Analysis]
|
| 3 |
Taddeo A, Veiga IB, Devisme C, Boss R, Plattet P, Weigang S, Kochs G, Thiel V, Benarafa C, Zimmer G. Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2. npj Vaccines 2022;7. [DOI: 10.1038/s41541-022-00508-7] [Reference Citation Analysis]
|
| 4 |
O’donnell KL, Gourdine T, Fletcher P, Clancy CS, Marzi A. Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1025500] [Reference Citation Analysis]
|
| 5 |
Espeseth AS, Yuan M, Citron M, Reiserova L, Morrow G, Wilson A, Horton M, Rukhman M, Kinek K, Hou F, Li SL, Li F, Choi Y, Heidecker G, Luo B, Wu G, Zhang L, Strable E, DeStefano J, Secore S, Mukhopadhyay TK, Richardson DD, Sayeed E, Welch LS, Bett AJ, Feinberg MB, Gupta SB, Cooper CL, Parks CL. Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera. EBioMedicine 2022;82:104203. [PMID: 35915046 DOI: 10.1016/j.ebiom.2022.104203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Parham KA, Kim GN, Saeedian N, Ninkov M, Richer CG, Li Y, Wu K, Rashu R, Barr SD, Arts EJ, Haeryfar SM, Kang CY, Troyer RM. Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants.. [DOI: 10.1101/2022.07.19.500626] [Reference Citation Analysis]
|
| 7 |
Taddeo A, Veiga IB, Devisme C, Boss R, Plattet P, Weigang S, Kochs G, Thiel V, Benarafa C, Zimmer G. Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior protective humoral immune response to SARS-CoV-2.. [DOI: 10.1101/2022.06.14.495413] [Reference Citation Analysis]
|
